• Meiji Seika Pharma extended its joint research with Rege Nephro and Kyoto University’s CiRA to develop therapies for intractable and rare diseases.
• The partners will use iPS cell-derived human disease models to analyze disease pathology and evaluate new treatment candidates.
• The collaboration aims to expand beyond small-molecule compounds into other therapeutic approaches, drawing on Meiji Seika Pharma’s drug discovery expertise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Meiji Holdings Co. Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.